Becton, Dickinson and Company (BDX) — Form 8-K Filing — May 20, 2026

Assembled Description

On May 20, 2026, Becton, Dickinson and Company (BDX) filed a Form 8-K with the Securities and Exchange Commission disclosing a significant capital markets transaction: the issuance of €600 million in aggregate principal amount of 3.855% Notes due 2033 by its indirect wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l. [Item 1.01 - Material Agreement, ¶1]. This refinancing transaction, in which the new notes are fully and unconditionally guaranteed on a senior unsecured basis by BD, replaces €600 million in lower-cost 1.208% notes maturing in June 2026 with longer-dated debt extending to 2033, reflecting a deliberate and strategic pivot in the company's capital management approach [Item 1.01 - Material Agreement, ¶2]. While this 8-K does not report quarterly earnings, segment-level financial results, or provide explicit fiscal guidance, the transaction it documents carries meaningful implications for BD's forward outlook, balance sheet positioning, interest cost profile, and strategic flexibility — all of which are examined in the sections below.

---

I. Forward Guidance and Strategic Outlook

While this May 20, 2026 8-K filing does not contain a traditional earnings release or explicit fiscal 2025 revenue and EPS guidance, it provides meaningful insight into BD's strategic capital management and financing approach as the company executes its long-term priorities.

Debt Refinancing as a Strategic Capital Move

BD, through its indirect wholly-owned subsidiary Becton Dickinson Euro Finance S.à r.l., issued €600 million aggregate principal amount of 3.855% Notes due 2033 [Item 1.01 - Material Agreement, ¶1]. The stated use of proceeds is to repay the entire aggregate principal amount outstanding of Becton Finance's 1.208% Notes due June 4, 2026, with any remaining net proceeds directed to general corporate purposes [Item 1.01 - Material Agreement, ¶6]. This refinancing extends BD's euro-denominated debt maturity profile by seven years — from the 2026 maturity to 2033 — locking in a fixed 3.855% coupon. While the new coupon reflects higher prevailing interest rates than the 1.208% notes being retired, the transaction reduces near-term refinancing risk and extends manageable debt obligations further into the future, consistent with a disciplined liability management strategy.

Innovation Pipeline and Long-Term Investment Capacity

The general corporate purposes allocation from the remaining proceeds supports BD's ability to fund ongoing investments in its innovation pipeline, including R&D in medical devices, diagnostic systems, and medication management solutions. By proactively managing its debt maturity schedule rather than facing a concentrated refinancing event, BD preserves financial flexibility to invest in strategic growth areas and pursue its long-term objectives without the overhang of imminent large-scale debt maturities.

Key Assumptions Embedded in the Capital Strategy

BD's decision to issue fixed-rate 3.855% notes through 2033 signals management's assumptions about the interest rate environment. Choosing fixed-rate rather than floating-rate debt suggests a view that current rates represent reasonable long-term borrowing costs, even if above the sub-2% levels of the prior low-rate environment. Additionally, the notes are fully and unconditionally guaranteed on a senior unsecured basis by BD [Item 1.01 - Material Agreement, ¶2], underscoring the parent company's confidence in its consolidated cash flows and credit profile to support subsidiary obligations throughout the note term.

Risks and Uncertainties Affecting the Outlook

The filing's debt covenants and structural terms highlight risk factors that could affect BD's forward trajectory. A Change of Control Triggering Event would require BD to offer to repurchase the notes at 101% of principal plus accrued interest [Item 1.01 - Material Agreement, ¶4], creating contingent liquidity demands. Tax law changes in Luxembourg, the U.S., or other relevant jurisdictions could trigger additional interest payment obligations [Item 1.01 - Material Agreement, ¶3]. The indenture's restrictive covenants — including limitations on liens, sale-and-leaseback transactions, and finance subsidiary activities — constrain BD's operational flexibility [Item 1.01 - Material Agreement, ¶6], potentially limiting how aggressively the company can pursue strategic alternatives such as large acquisitions or asset monetizations. Finally, event-of-default provisions tied to bankruptcy, insolvency, or covenant breach [Item 1.01 - Material Agreement, ¶4-5] reinforce that macroeconomic or company-specific deterioration could accelerate BD's debt obligations, adding risk to the forward outlook. In sum, this debt refinancing reflects BD's strategic approach to managing its capital structure while preserving flexibility for innovation and growth, though the associated covenants and contingent obligations introduce risks that investors should monitor against the company's broader fiscal outlook.

---

II. Debt Refinancing Transaction Terms and Covenants

At the center of this filing is a well-defined capital markets transaction with several structural features that merit close examination. Becton Dickinson Euro Finance S.à r.l., an indirect wholly-owned subsidiary of Becton, Dickinson and Company, issued €600,000,000 aggregate principal amount of 3.855% Notes due 2033 in an underwritten public offering [Item 1.01 - Material Agreement, ¶1]. The notes are fully and unconditionally guaranteed on a senior unsecured basis by BD, meaning that the parent company assumes direct responsibility for all payment obligations should the subsidiary fail to meet them [Item 1.01 - Material Agreement, ¶2].

Use of Proceeds

BD and Becton Finance expect to use the net proceeds from the offering, together with cash on hand, to repay the entire aggregate principal amount outstanding of Becton Finance's 1.208% Notes due June 4, 2026, along with accrued interest, fees, and expenses [Item 1.01 - Material Agreement, ¶6]. Any remaining net proceeds will be used for general corporate purposes. This refinancing replaces lower-cost debt (1.208%) with higher-cost debt (3.855%), which will increase BD's annual interest expense. However, extending the maturity to 2033 improves BD's liquidity profile by eliminating a concentrated near-term maturity wall and reducing refinancing risk.

Redemption Provisions

The notes include optional redemption provisions that give BD meaningful flexibility. Prior to February 20, 2033 (approximately three months before the maturity date), BD may redeem the notes at a make-whole redemption price based on the greater of par value or the sum of the present values of remaining scheduled payments discounted at the comparable government bond rate plus 15 basis points [Item 1.01 - Material Agreement, ¶2-3]. Thereafter, the notes are redeemable at par. This structure allows BD to refinance the notes early if market conditions become more favorable, while protecting noteholders from being called away at par well before maturity.

Change of Control and Tax-Related Provisions

The indenture includes investor-protection features that could create contingent obligations for BD. Upon a Change of Control Triggering Event, BD must offer to repurchase the notes at 101% of principal amount plus accrued and unpaid interest [Item 1.01 - Material Agreement, ¶4]. This provision protects noteholders in the event of an acquisition or similar transaction that materially alters BD's credit profile. Additionally, if changes in tax laws in Luxembourg, the U.S., or other relevant jurisdictions result in additional payment obligations, BD may be required to pay additional amounts to noteholders or, in some circumstances, redeem the notes early [Item 1.01 - Material Agreement, ¶3].

Indenture Covenants and Restrictions

The indenture governing the notes includes standard restrictive covenants that constrain BD's operational flexibility in specific ways. These include a limitation on liens that could otherwise secure indebtedness senior to the notes, a restriction on sale and leaseback transactions that could effectively create off-balance-sheet financing, and a restriction on Becton Finance engaging in activities inconsistent with its designation as a finance subsidiary [Item 1.01 - Material Agreement, ¶6]. While customary for investment-grade issuances, these covenants limit how aggressively BD can pursue certain strategic alternatives, such as large acquisitions financed through secured debt or asset monetizations involving sale-leaseback structures. Event-of-default provisions tied to bankruptcy, insolvency, failure to pay, or covenant breach [Item 1.01 - Material Agreement, ¶4-5] reinforce that macroeconomic or company-specific deterioration could accelerate BD's debt obligations. The information in Item 1.01 is incorporated by reference into Item 2.03 regarding the creation of a direct financial obligation [Item 2.03, ¶1].

---

III. Balance Sheet and Cash Flow Implications

Debt Issuance and Leverage Profile

The core balance sheet story centers on BD's proactive debt management. By issuing €600 million in new notes due 2033 and using those proceeds — together with cash on hand — to retire the €600 million in 1.208% Notes due June 2026, BD is effectively rolling over its euro-denominated debt at a materially higher coupon but across a significantly extended maturity timeline [Item 1.01 - Material Agreement, ¶1, ¶6]. This replacement of near-term obligations with longer-dated liabilities will reduce cash and cash equivalents on the balance sheet (to the extent that cash on hand is used alongside the note proceeds to cover accrued interest, fees, and expenses) while maintaining relatively stable total debt leverage in absolute euro terms. The net effect is a strengthening of BD's liquidity profile by pushing out maturities and reducing the concentration of obligations falling due in the near term.

Capital Allocation Discipline

The debt refinancing reflects BD's disciplined capital allocation approach, prioritizing liability management as a means of strengthening the balance sheet ahead of operational or acquisitive uses of capital. By proactively refinancing rather than allowing the 2026 notes to mature and become a refinancing emergency, BD management demonstrates a forward-looking approach to balance sheet management that prioritizes financial stability. The transaction does not increase BD's total euro-denominated debt — it simply extends the maturity profile — meaning that leverage ratios such as debt-to-EBITDA and debt-to-total-capital remain essentially unchanged in the immediate term, all else being equal.

Cash Flow Considerations

While this filing does not include a separate earnings release with operating cash flow or free cash flow figures, the transaction carries indirect cash flow implications. The higher coupon rate (3.855% versus 1.208%) will increase annual cash interest payments by approximately €15.9 million per year on the €600 million principal amount (calculated as the difference between 3.855% and 1.208% applied to €600 million). This represents a headwind to free cash flow in each year through 2033. However, the elimination of the 2026 maturity removes a significant near-term cash outflow — the repayment of €600 million in principal — that would have otherwise consumed a large portion of BD's available liquidity. On balance, the transaction trades higher annual cash interest expense for reduced refinancing risk and a more manageable debt maturity schedule.

---

IV. Revenue and Profitability Implications

While this Form 8-K does not report quarterly earnings results or provide specific revenue, gross margin, operating margin, or earnings per share data, the refinancing transaction it describes carries several implications for BD's future profitability profile that investors should consider.

Interest Expense Impact

The most direct profitability implication of this transaction is the increase in annual interest expense. BD is replacing €600 million in debt carrying a 1.208% coupon with debt carrying a 3.855% coupon — a spread of 264 basis points. On the €600 million principal amount, this equates to approximately €15.8 million in additional annual interest expense (€600 million × 2.647%). At current exchange rates, this translates to a meaningful reduction in pre-tax income and, after applying BD's effective tax rate, a reduction in net income and earnings per share. This incremental interest cost will recur annually through 2033, though it may be partially or fully offset by earnings growth from BD's ongoing operations, productivity initiatives, and the strategic benefits of the financial flexibility preserved by the refinancing.

Offset Through Operational Performance

The general corporate purposes allocation of remaining net proceeds supports BD's ability to fund ongoing investments in its innovation pipeline, including R&D in medical devices, diagnostic systems, and medication management solutions. To the extent that these investments generate revenue growth or cost savings that exceed the incremental interest cost, the net impact on profitability could be neutral or even positive. Investors should monitor BD's quarterly earnings releases for evidence of whether operational improvements are sufficient to offset the higher financing costs introduced by this refinancing.

Indirect Benefits to Profitability

By eliminating the June 2026 maturity concentration, BD reduces the risk that it would need to refinance at potentially even less favorable terms under time pressure or during a period of market disruption. This insurance-like benefit does not appear directly on the income statement but protects BD's profitability profile from tail risks that could be far more damaging than the incremental interest cost. Additionally, the fixed-rate nature of the new notes provides certainty around a portion of BD's interest costs through 2033, insulating the income statement from future interest rate increases on this particular debt tranche.

---

V. Segment Performance

This 8-K filing, dated May 20, 2026, relates to a debt financing transaction rather than an earnings announcement, and as such does not contain BD's typical segment performance disclosures. The filing captures a significant financing event for BD but does not report segment-level financial results for BD Medical, BD Life Sciences, or BD Interventional, nor does it include year-over-year revenue growth rates, organic growth metrics, currency impacts, segment operating margins, or new product launches.

The Refinancing's Indirect Segment Impact

While no specific segment impact is disclosed in this filing, the refinancing transaction may indirectly affect segment profitability at the consolidated level. The proceeds from this notes offering, together with cash on hand, are expected to be used to repay the entire aggregate principal amount outstanding of Becton Finance's 1.208% Notes due June 4, 2026, with any remaining net proceeds to be used for general corporate purposes [Item 1.01 - Material Agreement, ¶6]. To the extent that general corporate purposes include funding growth initiatives within specific business units, the transaction could support capital expenditure and R&D programs across BD's medical device, diagnostics, and interventional segments. The incremental interest expense discussed in Section IV will be recorded at the corporate level and will reduce consolidated net income, thereby flowing through to all segments' reported profitability on a consolidated basis.

Where to Find Segment Detail

Information regarding BD's segment performance is typically disclosed in quarterly earnings press releases furnished as Exhibits 99.1 to BD's periodic reports and in the Management's Discussion and Analysis sections of BD's 10-K and 10-Q filings. For a comprehensive view of BD's segment performance — including revenue by segment, organic growth rates, operating margins, and recent product developments — investors should refer to BD's most recent quarterly earnings press release and its Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as subsequent quarterly reports on Form 10-Q. The exhibits filed with this 8-K include the supplemental indenture, form of notes, and legal opinions [Item 9.01 - Exhibits, Table 1].

---

Conclusion

Becton, Dickinson and Company's May 20, 2026 8-K filing documents a carefully orchestrated debt refinancing that extends €600 million in euro-denominated obligations from a June 2026 maturity to 2033, locking in a 3.855% fixed coupon that is higher than the 1.208% rate being retired but providing seven additional years of financial flexibility. The transaction strengthens BD's balance sheet by eliminating a concentrated near-term maturity wall, reduces refinancing risk, and preserves the company's capacity to invest in its innovation pipeline across medical devices, diagnostics, and medication management. While the higher coupon creates a recurring annual interest expense headwind of approximately €15.8 million that will flow through to net income, this cost must be weighed against the strategic value of reduced refinancing uncertainty and the operational flexibility preserved. Investors should monitor BD's upcoming quarterly earnings releases for segment-level performance data and evidence that operating improvements are sufficient to offset the incremental financing costs introduced by this transaction.